Robert Kruit, chief executive for Zuellig Malaysia and Brunei, discusses Zuellig’s plans to expand beyond distribution and diversify its offering in the healthcare sector, and how Zuellig’s investments into digital health, commercial solutions, and animal health further the goal of making healthcare more accessible.
The pharmaceutical segment [in Malaysia] will continue to grow. Given that it is a large market and growing at a relatively fast rate, it remains an area of potential.
Rashidah Ibrahim, executive director of Malaysian Vaccines & Pharmaceuticals (MVP), tells the story of MVP as the sole animal vaccines manufacturer in Malaysia. She also explains how important animal health…
Sherene Azli, CEO of the Malaysia Healthcare Travel Council (MHTC), introduces this unique organization in charge of promoting Malaysia internationally as the ‘Cardiology and Fertility Hub of Asia’ and explains…
Chuwn Leong Ch’ng, CEO of Thunder Print, presents his company’s strategic role within the Malaysian healthcare industry to provide a high-quality packaging services for all type of health products, from…
Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for…
Writing in the September edition of DIA’s Global Forum magazine, Rosilawati Ahmad of Malaysia’s National Pharmaceutical Regulatory Agency; Tharnkamol Chanprapaph of the Thai FDA; and Samvel Azatyan, Valerio Reggi, and…
Eurasia Group’s Aditya Bhattacharji discusses the relatively modest scope of Malaysia’s recently-launched ‘MYSalam’ scheme; a healthcare programme which aims to provide coverage to the country’s bottom 40 percent of earners.…
See our Cookie Privacy Policy Here